ABSTRACT
Podoplanin (PDPN) is a small transmembrane mucin-like glycoprotein which is expressed on the surface of lymphatic endothelial cells, glomerular podocytes, type-Ⅰ alveolar epithelial cells and some tumor cells. PDPN plays crucial function in variety of physiological and pathological processes such as embryonic development, immunoreaction, inflammation and cancer. C-type lectin-like receptor 2 (CLEC2) is mainly expressed on the platelet which specific ligand is PDPN. The interaction between PDPN and CLEC2 has received extensive attention. In this review, we summarized recent researches on the role of in sepsis and elaborated the possible mechanisms and some potential therapies for sepsis by targeting PDPN, which may provide theoretical basis for the mechanism and treatment of sepsis.
ABSTRACT
The process of tumor metastasis is extremely complicated. The growing evidence indicates that platelets are closely involved in hematogenous metastasis of tumors. Platelets can secret an array of bioactive factors to help cancer cells evading immune surveillance and natural killer cell-mediated cytotoxicity, induce epithelialmesenchymal transition (EMT), proliferation, invasion of tumor cells, and subsequently promote cancer progression. Recent studies have showed that the interaction between platelet-activating C-type lectin-like receptor-2 (CLEC-2) and its ligand podoplanin (PDPN) can activate platelets and affect the proliferation, migration, and metastasis of tumor cells. Therefore, using anti-CLEC-2 antibody and blocking the CLEC-2/PDPN interaction maybe the novel anticancer treatments. This review illuminates the role of CLEC-2 in hematogenous metastasis of tumors and its clinical application prospect.